Isolated nocturnal hypertension and subclinical target organ damage: A systematic review of the literature

Hypertension Research

Volumn 38, Issue 8, 2015, Pages 570-575

  O'Flynn, Anne Marie ^a,b   Madden, Jamie M ^a   Russell, Audrey J ^a   Curtin, Ronan J ^a   Kearney, Patricia M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Ambulatory; blood pressure; blood pressure monitoring; cardiovascular diseases; circadian rhythm; target organ damage

Indexed keywords

ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; COCHRANE LIBRARY; ELECTROCARDIOGRAM; EMBASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; ISOLATED NOCTURNAL HYPERTENSION; MEDLINE; ORGAN INJURY; POPULATION; PROTEINURIA; PULSE WAVE; SYSTEMATIC REVIEW; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 84938765561     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2015.43     Document Type: Article

References (31)

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C , Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arteri al hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
2. http://www.nice.org.uk/guidance/CG127. National Institute for Health and Care Excellence 2011.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ. Joint national committ ee on prevention, detection, evaluation, and treatment of high blood pressure. national heart, lung, and blood institute; national high blood pressure education program coordinating committee. seventh report of the joint national committee on pr evention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
4. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension 2011; 57: 3-10.
5. de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, de la Cruz JJ, Sobrino J, Llisterri JL, Alonso J, Vinyoles E, Pallarés V, Sarría A, Aranda P, Ruilope LM. Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investi gators. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 2009; 53: 466-472.
6. Perez-Lloret S, Toblli JE, Cardinali DP, Malateste JC, Milei J. Nocturnal hypertension defined by fixed cut-off limits is a better predictor of left ventricular hypertrophy than non-dipping. Int J Cardiol 2008; 127: 387-389.
7. Tsioufis C, Andrikou I, Tho mopoulos C, Petras D, Manolis A, Stefanadis C. Comparative prognostic role of nighttime blood pressure and nondipping profile on renal outcomes. Am J Nephrol 2011; 33: 277-288.
8. Tsioufis C, Andrikou I, Thomopoulos C, Syrseloudis D, Stergiou G, Stefanadis C. Increased nighttime blood pressure or nondipping profile for prediction of cardiovascular outcomes. J Hum Hypertens 2010; 25: 281-293.
9. Li Y, Staessen JA, Lu L, Li L-H, Wang G-L, Wang J-G. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. Hypertension 2007; 50: 333-339.
10. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Björklund-Bodegå rd K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA. International Database on Ambulatory Blood Pressure In Relation to Cardiovascular O u tcomes Investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hyperten 2010; 28: 2036-2045.
11. Chronic Kidney Disease Prognosis Co nsortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-Analysis. Lancet 2010; 375: 2073-2081.
12. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline ele ctrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
13. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
14. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
15. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt P, Olsen MH. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-891.
16. Volpe M, Battistoni A, Tocci G, Rosei EA, Catapano AL, Coppo R, del Prato S, Gentile S, Mannarino E, Novo S, Prisco D, Mancia G. Cardiovascular risk assessment beyond S ystemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens 2012; 30: 1056-1064.
17. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427-437.
18. Lu L, Li Y, Huang QF. The relationship between isolated nocturnal hypertension and left ventricular hypertrophy. Zhonghua nei ke za zhi 2008; 47: 819-822.
19. Wijkman M,Länne T,Engvall J,Lindström T Ostgren CJ Nystrom FH. Masked noctu rnal hypertension-A novel marker of risk in type 2 diabetes. Diabetologia 2009 52 1258-1264.
20. Ogedegbe G, Spruill TM, Sarpong DF, Agyemang C, Chaplin W, Pastva A, Martins D, Ravenell J, Pickering TG. Correlates of isolated nocturnal hypertension and target organ damage in a population-based cohort of African Americans: the Jackson Heart Study. Am J Hypertens 2013; 26: 1011-1016.
21. Le vy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990; 81: 815-82 0.
22. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf BLIFE Study Investigators. Regressio n of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-2349.
23. White WB, Larocca GM. Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping " proportion. Am J Cardiol 2003; 92: 1439-1441.
24. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006; 332: 1080.
25. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25: 127-141.
26. Li Y, Wang J-G. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension 2013; 61: 278-283.
27. Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2013; 36: 262-269.
28. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790-795.
29. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
30. Mancini GBJ, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004; 109: IV22-IV30.
31. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004; 109: IV31-IV46.